

Caterina De Luca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5713592/publications.pdf>

Version: 2024-02-01

55
papers

1,208
citations

346980

22
h-index

445137

33
g-index

55
all docs

55
docs citations

55
times ranked

1520
citing authors

#	ARTICLE	IF	CITATIONS
1	MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice. <i>Journal of Clinical Pathology</i> , 2023, 76, 492-496.	1.0	5
2	Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel. <i>Journal of Clinical Pathology</i> , 2022, 75, 465-471.	1.0	6
3	Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , 2022, 75, 350-353.	1.0	6
4	RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center. <i>Personalized Medicine</i> , 2022, 19, 395-401.	0.8	2
5	Predictive molecular pathology in the time of COVID-19. <i>Journal of Clinical Pathology</i> , 2021, 74, 234-237.	1.0	13
6	RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 139.	1.7	17
7	Cytopathology practice during the COVID-19 postlockdown: An Italian experience. <i>Cancer Cytopathology</i> , 2021, 129, 548-554.	1.4	15
8	Cytopathology Practice in the COVID-19 Era: Focus on Sample Workload. <i>Journal of Molecular Pathology</i> , 2021, 2, 109-113.	0.5	2
9	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103300.	2.0	6
10	PD-L1 and beyond: Immunooncology in cytopathology. <i>Cytopathology</i> , 2021, 32, 596-603.	0.4	11
11	Molecular Testing of Thyroid Fine-Needle Aspiration: Local Issues and Solutions. An Interventional Cytopathologist Perspective. <i>Journal of Molecular Pathology</i> , 2021, 2, 233-240.	0.5	2
12	Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. <i>Cells</i> , 2021, 10, 1878.	1.8	32
13	Methods for actionable gene fusion detection in lung cancer: now and in the future. <i>Pharmacogenomics</i> , 2021, 22, 833-847.	0.6	4
14	Tumor mutational burden on cytological samples: A pilot study. <i>Cancer Cytopathology</i> , 2021, 129, 460-467.	1.4	34
15	Rapid On-site Molecular Evaluation in thyroid cytopathology: A same-day cytological and molecular diagnosis. <i>Diagnostic Cytopathology</i> , 2020, 48, 300-307.	0.5	16
16	Understanding EGFR heterogeneity in lung cancer. <i>ESMO Open</i> , 2020, 5, e000919.	2.0	32
17	Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report. <i>Journal of Molecular Pathology</i> , 2020, 1, 36-42.	0.5	1
18	Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: a retrospective study. <i>Journal of Clinical Pathology</i> , 2020, , jclinpath-2020-207107.	1.0	8

#	ARTICLE	IF	CITATIONS
19	KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. <i>Journal of Thoracic Disease</i> , 2020, 12, 3836-3843.	0.6	47
20	Molecular predictive testing in precision oncology: The Italian experience. <i>Cancer Cytopathology</i> , 2020, 128, 622-628.	1.4	2
21	Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. <i>Cells</i> , 2020, 9, 2019.	1.8	30
22	Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe [®] Panel. <i>Frontiers in Oncology</i> , 2020, 10, 236.	1.3	11
23	Diagnostic accuracy of p53 immunohistochemistry as surrogate of TP53 sequencing in endometrial cancer. <i>Pathology Research and Practice</i> , 2020, 216, 153025.	1.0	30
24	Evaluation of <i>KRAS</i> , <i>NRAS</i> and <i>BRAF</i> mutational status and microsatellite instability in early colorectal carcinomas invading the <i>submucosa</i> (pT1): towards an in-house molecular prognostication for pathologists?. <i>Journal of Clinical Pathology</i> , 2020, 73, 741-747.	1.0	9
25	PD-L1 expression in cell blocks of non-small cell lung cancer: The impact of prolonged fixation. <i>Diagnostic Cytopathology</i> , 2020, 48, 595-603.	0.5	9
26	Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx. <i>Diagnostic Cytopathology</i> , 2020, 48, 759-764.	0.5	3
27	Immunohistochemical Nuclear Expression of β -Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer. <i>American Journal of Clinical Pathology</i> , 2019, 151, 529-538.	0.4	70
28	Bird's eye view of modern cytopathology: Report from the seventh international Molecular Cytopathology Meeting in Naples, Italy, 2018. <i>Cancer Cytopathology</i> , 2019, 127, 350-357.	1.4	3
29	Is the Idylla <i>EGFR</i> Mutation Assay feasible on archival stained cytological smears? A pilot study. <i>Journal of Clinical Pathology</i> , 2019, 72, 609-614.	1.0	14
30	PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. <i>Journal of Clinical Pathology</i> , 2019, 72, 412-417.	1.0	26
31	Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples. <i>Journal of Clinical Pathology</i> , 2019, 72, 38-45.	1.0	37
32	Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm. <i>Journal of Clinical Pathology</i> , 2018, 71, 745-750.	1.0	32
33	EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review. <i>Translational Cancer Research</i> , 2018, 8, S64-S69.	0.4	15
34	EGFR mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based Idylla EGFR Mutation Assay. <i>Journal of Clinical Pathology</i> , 2017, 70, 295-300.	1.0	44
35	Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. <i>British Journal of Cancer</i> , 2017, 116, 802-810.	2.9	124
36	Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study. <i>Journal of Clinical Pathology</i> , 2017, 70, 803-806.	1.0	13

#	ARTICLE	IF	CITATIONS
37	There is still a role for cytology in the "liquid biopsy"™ era. A lesson from a TKI-treated patient showing adenocarcinoma to squamous cell carcinoma transition during disease progression. <i>Journal of Clinical Pathology</i> , 2017, 70, 798-802.	1.0	16
38	Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. <i>Journal of Thoracic Disease</i> , 2017, 9, S1383-S1390.	0.6	39
39	KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test. <i>CytoJournal</i> , 2017, 14, 5.	0.8	9
40	Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. <i>Journal of Clinical Pathology</i> , 2016, 69, 986-991.	1.0	28
41	EGFR mutation detection on routine cytological smears of non-small cell lung cancer by digital PCR: a validation study. <i>Journal of Clinical Pathology</i> , 2016, 69, 454-457.	1.0	22
42	EGFR mutation detection on lung cancer cytological specimens by the rapid and fully integrated Idylla molecular diagnostics system.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20542-e20542.	0.8	0
43	Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine needle aspirates.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15726-e15726.	0.8	0
44	Ciliated foregut cyst of the pancreas: A benign lesion with elevated CEA levels. <i>Diagnostic Cytopathology</i> , 2015, 43, 178-180.	0.5	5
45	Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective. <i>Cytopathology</i> , 2015, 26, 271-283.	0.4	76
46	EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer. <i>Journal of Clinical Pathology</i> , 2015, 68, 739-741.	1.0	6
47	Performance of EGFR mutant-specific antibodies in different cytological preparations: a validation study. <i>Cytopathology</i> , 2015, 26, 99-105.	0.4	7
48	Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?. <i>Cytopathology</i> , 2015, 26, 312-317.	0.4	30
49	Epidermal Growth Factor Receptor Test Performed on Liquid-Based Cytology Lung Samples: Experience of an Academic Referral Center. <i>Acta Cytologica</i> , 2014, 58, 589-594.	0.7	37
50	EGFR analysis: Current evidence and future directions. <i>Diagnostic Cytopathology</i> , 2014, 42, 984-992.	0.5	36
51	KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. <i>Journal of Clinical Pathology</i> , 2014, 67, 1-9.	1.0	30
52	EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. <i>Cancer Cytopathology</i> , 2013, 121, 552-560.	1.4	71
53	EGFR mutation detection by microfluidic technology: a validation study. <i>Journal of Clinical Pathology</i> , 2013, 66, 982-984.	1.0	12
54	Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. <i>Journal of Clinical Pathology</i> , 2012, 65, 940-944.	1.0	29

#	ARTICLE	IF	CITATIONS
55	KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. British Journal of Cancer, 2012, 107, 626-631.	2.9	24